Stay tuned and follow the latest developments and news in Molecular Oncology.
RediScore® is a test developed to predict the presence of HRD through the analysis of the tumor’s genomic instability. RediScore® is a test developed to predict the presence of HRD through the analysis of the tumor’s genomic instability. It is based on the technology of SNP (Single Nucleotide Polymotphisms), which is the standard method for the analysis of abnormal chromosomal structures formed as a result of the Homologous Recombination Deficiency. Combined with the analysis of mutations of the BRCA1 / 2 genes in the tumor, it gives us a comprehensive picture of the functionality of the HR pathway.
When is RediScore Test Significant?
The RediScore® test is recommended for all patients with ovarian cancer, but also where the use of PARP inhibitors is under investigation for treatment or maintenance treatment of the patient.
Why is The RediScore Test Significant?
It has now been proven by a plethora of clinical studies that about 50% of ovarian cancer patients could benefit from the administration of PARP inhibitors. These include patients with: These include patients with:
Since 2014, four PARP inhibitors (PARPi) have been approved by the FDA: Olaparib, Niraparib, Rucaparib, and Talazoparib. Their administration has been approved for 4 types of cancer: ovarian, prostate, pancreatic and breast cancer.
Sample type – Tissue enclosed in a paraffin block
Delivery time – 15 working days
Learn more about the assay https://www.genekor.com/el/services/rediscore/
Please contact Genekor Customer Service for more information on testing. info@genekor.com – Tel: 210 6032138